ÂÜŔňÂŇÂ×

As President, Global Drug Development & Chief Medical Officer for Novartis, Shreeram Aradhye is responsible for advancing the Novartis pipeline of investigational medicines to bring transformative new treatment options to patients with serious diseases.

Shreeram’s organization leads the clinical development of potential new medicines, running large clinical trials and steering the path to regulatory approval, while also maintaining oversight of ongoing patient safety and regulatory activities for licensed therapies. With an aim to bring up to 20 major new medicines to patients by 2026 – including for cardiovascular and immunological conditions, neurological disorders and various forms of cancer – Shreeram and his team play a central role in driving the company’s long-term growth and delivering on its purpose to improve and extend people’s lives.

Shreeram is passionate about developing investigational medicines, recognizing the hope and trust of patients participating in clinical trials. He has dedicated his professional career to improving patients’ lives, first as an academic clinician and then as a drug developer and business leader.

Shreeram took on his current role at Novartis in May 2022, rejoining the company after spending several years at US biotechnology companies, including leading the development of multiple clinical stage RNAi assets at Dicerna Pharmaceuticals. He first joined Novartis in 1999 and over the course of 20 years held a succession of leadership roles in the US, Switzerland, Germany and India, including Global Head of Medical Affairs for the Pharmaceuticals Business Unit and Development Head for the Neuroscience Franchise.

Before joining the life sciences industry, Shreeram was an attending physician and assistant professor of medicine and a transplant nephrologist at the University of Pennsylvania. He completed his medical training at the All India Institute of Medical Sciences in 1989, after which he received additional specialty training in internal medicine and nephrology in the US.